ANI PharmaceuticalsANIP
About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Employees: 642
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 60
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
0.89% less ownership
Funds ownership: 92.84% [Q3] → 91.95% (-0.89%) [Q4]
2% less funds holding
Funds holding: 207 [Q3] → 203 (-4) [Q4]
9% less capital invested
Capital invested by funds: $1.17B [Q3] → $1.07B (-$106M) [Q4]
69% less call options, than puts
Call options by funds: $188K | Put options by funds: $597K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JP Morgan Ekaterina Knyazkova 0 / 0 met price target | 37%upside $85 | Overweight Initiated | 12 Mar 2025 |
Guggenheim Vamil Divan 44% 1-year accuracy 11 / 25 met price target | 38%upside $86 | Buy Maintained | 5 Mar 2025 |
HC Wainwright & Co. Oren Livnat 56% 1-year accuracy 27 / 48 met price target | 51%upside $94 | Buy Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 16 articles about ANIP published over the past 30 days
